Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-alcoholic Steatohepatitis (NASH) Clear all
Completed Phase 2 Interventional

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

NCT06342947
View directory record Official record
Conditions
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
Interventions
ALG-055009, Placebo
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
40
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates

NCT00887393
View directory record Official record
Conditions
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Interventions
low carbohydrate diet, low-fat diet
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 14, 2026, 1:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

NCT05604287
View directory record Official record
Conditions
Healthy Participants
Interventions
ID119031166M, Placebo
Drug
Lead sponsor
IlDong Pharmaceutical Co Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

NCT02077374
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Miami, Florida • Indianapolis, Indiana • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 14, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

NCT03053050
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
124
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Completed No phase listed Observational

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
7,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Palo Alto, California • Pasadena, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Interventions
Lanifibranor, Placebo, Empagliflozin
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

Healthy Eating Through Reduction Of Excess Sugar

NCT02948647
View directory record Official record
Conditions
NAFLD
Interventions
Standard of care plus sugar-reduction education
Other
Lead sponsor
University of Southern California
Other
Eligibility
12 Years to 18 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 14, 2026, 1:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions
Pegozafermin, Placebo
Biological · Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
150
States / cities
Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity

NCT02787668
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Childhood Obesity, Insulin Resistance
Interventions
Carbohydrate-restricted diet, Control, low-fat diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 3 Interventional

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

NCT02132442
View directory record Official record
Conditions
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
Interventions
Ergocalciferol, placebo
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

NCT04709913
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 14, 2026, 1:30 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

NCT04065841
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor, Licogliflozin, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

NASH Fitness Intervention in Thrombosis Trial (NASHFit)

NCT03518294
View directory record Official record
Conditions
Liver Diseases, Blood Disorder, Digestive System Disease
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 14, 2026, 1:30 AM EDT
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

NCT01679197
View directory record Official record
Conditions
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis

NCT01766713
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Ezetimibe
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

NAFLD in Adolescents and Young Adults With PCOS

NCT02506946
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed No phase listed Observational

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05320146
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
MRI-PDFF
Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Timeline
2022 – 2023
U.S. locations
9
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

NCT02279524
View directory record Official record
Conditions
Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
Interventions
Aramchol
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Chula Vista, California • Los Angeles, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 14, 2026, 1:30 AM EDT
Recruiting No phase listed Observational

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

NCT05728697
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions
Endoscopic ultrasound shear wave elastography
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children

NCT02383485
View directory record Official record
Conditions
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Interventions
Exercise, After-school program
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 11 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

Effects of Alanine in Patients With Nonalcoholic Steatohepatitis

NCT00586885
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
L-alanine
Drug
Lead sponsor
Keith D Lindor, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 14, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NCT04054310
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Liver Multi Scan
Diagnostic Test
Lead sponsor
Perspectum
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Chandler, Arizona • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 1:30 AM EDT